SMT202000398T1 - Benzazepine fuse per il trattamento della balbuzie - Google Patents

Benzazepine fuse per il trattamento della balbuzie

Info

Publication number
SMT202000398T1
SMT202000398T1 SM20200398T SMT202000398T SMT202000398T1 SM T202000398 T1 SMT202000398 T1 SM T202000398T1 SM 20200398 T SM20200398 T SM 20200398T SM T202000398 T SMT202000398 T SM T202000398T SM T202000398 T1 SMT202000398 T1 SM T202000398T1
Authority
SM
San Marino
Prior art keywords
stuttering
treatment
fused benzazepines
benzazepines
fused
Prior art date
Application number
SM20200398T
Other languages
English (en)
Inventor
Richard E Chipkin
Original Assignee
Emalex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emalex Biosciences Inc filed Critical Emalex Biosciences Inc
Publication of SMT202000398T1 publication Critical patent/SMT202000398T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SM20200398T 2013-10-18 2014-10-17 Benzazepine fuse per il trattamento della balbuzie SMT202000398T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892841P 2013-10-18 2013-10-18
PCT/US2014/061080 WO2015058053A1 (en) 2013-10-18 2014-10-17 Fused benzazepines for treatment of stuttering
EP14854586.6A EP3057595B1 (en) 2013-10-18 2014-10-17 Fused benzazepines for treatment of stuttering

Publications (1)

Publication Number Publication Date
SMT202000398T1 true SMT202000398T1 (it) 2020-09-10

Family

ID=52828726

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200398T SMT202000398T1 (it) 2013-10-18 2014-10-17 Benzazepine fuse per il trattamento della balbuzie

Country Status (19)

Country Link
US (1) US9949983B2 (it)
EP (1) EP3057595B1 (it)
JP (3) JP2016533374A (it)
AU (1) AU2014337140B2 (it)
CA (1) CA2927915C (it)
CY (1) CY1123121T1 (it)
DK (1) DK3057595T3 (it)
ES (1) ES2805448T3 (it)
HR (1) HRP20201152T1 (it)
HU (1) HUE049848T2 (it)
IL (1) IL245155B (it)
LT (1) LT3057595T (it)
MX (1) MX370612B (it)
PL (1) PL3057595T3 (it)
PT (1) PT3057595T (it)
RS (1) RS60556B1 (it)
SI (1) SI3057595T1 (it)
SM (1) SMT202000398T1 (it)
WO (1) WO2015058053A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2872145T3 (pl) 2012-07-12 2022-06-20 Emalex Biosciences, Inc. Połączone benzazepiny w leczeniu zespołu tourette’a
EP3628316A4 (en) 2017-03-30 2021-04-14 Penello Temporão, José Eduardo MULTI-VITAMIN COMPOSITION TO IMPROVE VERB FLUIDITY AND REDUCE SYMPTOMS OF PERFORMANCE ANXIETY AND ITS PREPARATION PROCESS
RU2019143572A (ru) * 2017-05-25 2021-06-25 Глитек Ллс. Композиции для лечения посттравматического стрессового расстройства
US10786495B2 (en) * 2017-10-10 2020-09-29 The Regents Of The University Of California Vesicular monoamine transporter 2 inhibitors for treating stuttering
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3972573A4 (en) * 2019-05-23 2023-07-12 India Globalization Capital, Inc. COMPOSITIONS AND METHODS OF USING CANNABINOIDS TO TREAT STAMMING/STOMMING AND SYMPTOMS OF TOURETTE SYNDROME
US12594281B2 (en) 2024-03-15 2026-04-07 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4973586A (en) 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
US5302716A (en) 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
BE1005064A4 (nl) 1991-07-03 1993-04-06 Asm Fico Tooling Buiginrichting.
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
WO1995025102A1 (en) 1994-03-16 1995-09-21 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
KR20010031470A (ko) * 1997-10-28 2001-04-16 둘락 노먼 씨. 포유동물의 갈망을 감소시키는 방법
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2012033874A1 (en) 2010-09-10 2012-03-15 Chipkin Richard E Method of treating compulsive self-injurious behaviors
PL2872145T3 (pl) 2012-07-12 2022-06-20 Emalex Biosciences, Inc. Połączone benzazepiny w leczeniu zespołu tourette’a

Also Published As

Publication number Publication date
LT3057595T (lt) 2020-08-10
IL245155B (en) 2020-07-30
MX370612B (es) 2019-12-18
WO2015058053A1 (en) 2015-04-23
JP2019147843A (ja) 2019-09-05
IL245155A0 (en) 2016-06-30
EP3057595B1 (en) 2020-04-29
SI3057595T1 (sl) 2020-09-30
JP2021080288A (ja) 2021-05-27
NZ719103A (en) 2021-05-28
HRP20201152T1 (hr) 2020-10-30
US9949983B2 (en) 2018-04-24
ES2805448T3 (es) 2021-02-12
US20160271141A1 (en) 2016-09-22
RS60556B1 (sr) 2020-08-31
JP7245509B2 (ja) 2023-03-24
CA2927915C (en) 2021-10-26
PL3057595T3 (pl) 2021-03-08
EP3057595A1 (en) 2016-08-24
DK3057595T3 (da) 2020-08-10
MX2016005030A (es) 2017-01-23
CA2927915A1 (en) 2015-04-23
JP2016533374A (ja) 2016-10-27
HUE049848T2 (hu) 2020-11-30
EP3057595A4 (en) 2017-06-07
CY1123121T1 (el) 2021-10-29
PT3057595T (pt) 2020-07-31
AU2014337140A1 (en) 2016-05-12
AU2014337140B2 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
GB2516725B (en) Neck Orthosis
SG11201506876XA (en) Modification of polypeptides
AU356625S (en) Rollator
GB2519934B (en) Improved shisha
AU352456S (en) Process tube
SG11201603028SA (en) Purification of proteins
IL245155A0 (en) Benzazepines are combined for the treatment of stuttering
SG11201505204VA (en) Protein purification process
IL245379A0 (en) Heterocyclic n-acylamino compounds
IL240613A0 (en) bicyclic compounds
EP3065944A4 (en) Modification of polyamides
GB201308466D0 (en) Improved process for treatment of minewater
IL244347A0 (en) n-acylamino heterocyclic compounds
GB2539112B (en) Chlorination of sucrose-6-esters
ZA201601248B (en) Wheelchair
AU347055S (en) Jug
GB201303796D0 (en) Condom
GB2514324B (en) Modified tubular
GB201300649D0 (en) Cyclization
GB201301722D0 (en) Quantifcation of bacteria
GB201322366D0 (en) Chlorination of sucrose-6-esters
GB201314779D0 (en) Chlorination of sucrose-6-esters
PH32013000344S1 (en) Jug
IL225151A0 (en) Hookah capsule
AU352921S (en) Serving jug